MedTrace Logo

Cabazitaxel and Prednisone in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

NCT02844582 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2021-01-25

Study results available
· View outcomes & findings →

Summary

This phase II trial studies how well cabazitaxel and prednisone work in treating patients with hormone-resistant prostate cancer that has spread to other parts of the body. Drugs used in chemotherapy, such as cabazitaxel and prednisone, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

Conditions

  • Hormone-Resistant Prostate Cancer
  • Stage IV Prostate Adenocarcinoma

Interventions

DRUG

Cabazitaxel

Given IV

DRUG

Prednisone

Given PO

Sponsors & Collaborators

  • Sanofi

    collaborator INDUSTRY

  • University of California, Davis

    lead OTHER

Principal Investigators

  • Christopher Evans · University of California, Davis

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-12-20
Primary Completion
2019-06-04
Completion
2019-06-04
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02844582 on ClinicalTrials.gov